» Articles » PMID: 33407746

Metaplastic Carcinoma of the Breast and BRCA1 Germline Mutation: a Case Report and Review

Abstract

Background: Metaplastic carcinoma of the breast consists of both invasive ductal carcinoma and metaplastic carcinoma. This rare subtype of cancer has a poor prognosis. The development of metaplastic breast cancer and relationship with BRCA1 are not well known. Here, we report a rare case of germline BRCA1 mutation-positive breast cancer with chondroid metaplasia.

Case Presentation: A 39-year-old Japanese woman with a family history of breast cancer in her mother and ovarian cancer in her maternal grandmother consulted at our hospital with a left breast mass. Needle biopsy for the mass was performed, leading to a diagnosis of invasive breast cancer with chondroid metaplasia. We performed left mastectomy + sentinel lymph node biopsy + tissue expander insertion and replaced with a silicone implant later. Pathological examination revealed that the patient had triple-negative breast cancer. Four courses of doxorubicin+ cyclophosphamide therapy were performed as adjuvant therapy after surgery. We performed genetic counseling and genetic testing, and the results suggested the germline BRCA1 mutation 307 T> A (L63*). She has currently lived without a relapse for 2 years post-surgery.

Conclusions: There have been only 6 cases of metaplastic breast carcinoma with germline BRCA1 mutations including our case. Patients with BRCA1 mutations may develop basal-like subtypes or M type of triple-negative breast cancer besides metaplastic breast cancers.

Citing Articles

Pathogenic Germline Variants in Patients With Metaplastic Breast Cancer.

Demarest K, Anantharajah A, Maxwell K, Rohanizadegan M, Bradbury A, Nathanson K JAMA Netw Open. 2025; 8(2):e2460312.

PMID: 39964682 PMC: 11836754. DOI: 10.1001/jamanetworkopen.2024.60312.


Direct DNA binding by BRCA1 on β-hCG promoter and its clinical implications.

Krishnan N, R L N, Warrier A, Yadev I, Anandan J, Sundaram S Heliyon. 2024; 10(17):e37064.

PMID: 39286065 PMC: 11403530. DOI: 10.1016/j.heliyon.2024.e37064.


Germline pathogenic variants in metaplastic breast cancer patients and the emerging role of the BRCA1 gene.

Corso G, Marabelli M, Calvello M, Gandini S, Risti M, Feroce I Eur J Hum Genet. 2023; 31(11):1275-1282.

PMID: 37460658 PMC: 10620155. DOI: 10.1038/s41431-023-01429-2.


Metaplastic Breast Carcinoma Presenting as a Mixed Solid and Cystic Lesion.

Arekemase H, Mohammed O, Zafar U, Manpreet K, Maghari A Cureus. 2022; 14(2):e22029.

PMID: 35340469 PMC: 8913436. DOI: 10.7759/cureus.22029.

References
1.
Suspitsin E, Sokolenko A, Voskresenskiy D, Ivantsov A, Shelehova K, Klimashevskiy V . Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier. Breast Cancer. 2009; 18(2):137-40. DOI: 10.1007/s12282-009-0105-0. View

2.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

3.
Lehmann B, Jovanovic B, Chen X, Estrada M, Johnson K, Shyr Y . Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11(6):e0157368. PMC: 4911051. DOI: 10.1371/journal.pone.0157368. View

4.
Bellino R, Arisio R, DAddato F, Attini R, Durando A, Danese S . Metaplastic breast carcinoma: pathology and clinical outcome. Anticancer Res. 2003; 23(1B):669-73. View

5.
Weigelt B, Kreike B, Reis-Filho J . Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2008; 117(2):273-80. DOI: 10.1007/s10549-008-0197-9. View